Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis

Summary

Rivaroxaban, an oral, direct factor Xa inhibitor, has been approved for the treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE as a fixed-dose, single-drug regimen that does not require initial heparinisation, routine coagulation monitoring or dose adjustment. This study evaluated patient-reported treatment satisfaction in EINSTEIN DVT - a large, open-label, randomised study that compared rivaroxaban with enoxaparin/ vitamin K antagonist (VKA) therapy in patients with acute symptomatic DVT without PE. As part of EINSTEIN DVT, a total of 1,472 patients in seven countries were asked to complete a new, validated measure of treatment satisfaction - the Anti-Clot Treatment Scale (ACTS) - at scheduled visits throughout 12 months of treatment. ACTS scores were compared between study groups in the intentionto- treat population. Patients reported greater satisfaction in the rivaroxaban group compared with the enoxaparin/VKA group, with higher mean ACTS scores across visits. Mean ACTS Burdens scores were 55.2 vs 52.6 (p<0.0001) in favour of rivaroxaban, equivalent to a moderate effect size of 0.42. The treatment effect was consistent over time, with the mean score difference ranging from 2.18 (month 2) to 3.18 (month 12). Overall mean ACTS Benefits scores were 11.7 vs 11.5 in favour of rivaroxaban (p=0.006). This was associated with a small overall effect size of 0.12. The improvement in ACTS Benefits for rivaroxaban became apparent at month 2 and subsequent visits. Rivaroxaban results in improved treatment satisfaction compared with enoxaparin/VKA among patients with DVT, particularly in reducing patient-reported anticoagulation burden.

Keywords

PRO instruments - rivaroxaban - treatment satisfaction - venous thromboembolism

• References

• 1 Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83: 657-660.
• 2 Spencer FA, Emery C, Lessard D. et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-727.
• 3 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: 14-18.
• 4 Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005; 3: 1611-1617.
• 5 Carson JL, Kelley MA, Duff A. et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-1245.
• 6 Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2006; CD001367.
• 7 Prandoni P, Lensing AWA, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
• 8 Rodger MA, Kahn SR, Wells PS. et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179: 417-426.
• 9 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e419S-e494S.
• 10 Ansell J, Hirsh J, Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 160S-198S.
• 11 Nutescu EA, Shapiro NL, Ibrahim S. et al. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 2006; 5: 433-451.
• 12 Wells PS, Holbrook AM, Crowther NR. et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676-683.
• 13 Lee AY, Hirsh J. Diagnosis and treatment of venous thromboembolism. Annu Rev Med 2002; 53: 15-33.
• 14 Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
• 15 Barbosa CD, Balp MM, Kulich K. et al. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence 2012; 6: 39-48.
• 16 Pisters R, de Vos CB, Nieuwlaat R. et al. Use and underuse of oral anticoagulation for stroke prevention in atrial fibrillation: old and new paradigms. Semin Thromb Hemost 2009; 35: 554-559.
• 17 Samsa G, Matchar DB, Dolor RJ. et al. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes 2004; 2: 22.
• 18 Wild D, Murray M, Shakespeare A. et al. Patient-reported treatment satisfaction measures for long-term anticoagulant therapy. Expert Rev Pharmacoecon Outcomes Res 2008; 8: 291-299.
• 19 Wild D, Murray M, Donatti C. Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 467-474.
• 20 Cano SJ, Lamping DL, Bamber L. et al. The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes 2012; 10: 120.
• 21 Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf Accessed May 23, 2013.
• 22 The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
• 23 Atkinson MJ, Kumar R, Cappelleri JC. et al. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005; 8 (Suppl. 01) S9-S24.
• 24 Bharmal M, Payne K, Atkinson MJ. et al. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes 2009; 7: 36.
• 25 Atkinson MJ, Sinha A, Hass SL. et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
• 26 Hochberg Y. A sharper Bonferroni procedure for multiple tests for significance. Biometrika 1988; 75: 800-802.
• 27 Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New Jersey: Lawrence Erlbaum; 1988. .
• 28 Turner EH, Rosenthal R. Efficacy of antidepressants: Is not an absolute measure, and it depends on how clinical significance is defined. Br Med J 2008; 336: 516-517.
• 29 Kraemer HC, Morgan GA, Leech NL. et al. Measures of clinical significance. J Am Acad Child Adolesc Psychiatry 2003; 42: 1524-1529.
• 30 Perzborn E, Roehrig S, Straub A. et al. The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor. Nat Rev Drug Discov 2011; 10: 61-75.
• 31 Büller HR, Halperin JL, Bounameaux H. et al. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. J Thromb Haemost 2008; 6: 227-229.
• 32 Prins M, Bamber L, Cano S. et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood (ASH Annual Meeting Abstracts). 2012. 120 Abstract 1163
• 33 Coleman CI, Coleman SM, Vanderpoel J. et al. Patient satisfaction with warfarin- and non-warfarin-containing thromboprophylaxis regimens for atrial fibrillation. J Investig Med 2013; 61: 878-881.
• 34 Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582-592.
• 35 Lemieux J, Beaton DE, Hogg-Johnson S. et al. Three methods for minimally important difference: no relationship was found with the net proportion of patients improving. J Clin Epidemiol 2007; 60: 448-455.
• 36 Hobart JC, Cano SJ, Zajicek JP. et al. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 2007; 6: 1094-1105.
• 37 Klassen AF, Pusic AL, Scott A. et al. Satisfaction and quality of life in women who undergo breast surgery: a qualitative study. BMC Womens Health 2009; 9: 11.
• 38 MacLean S, Mulla S, Akl EA. et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e1S-e23S.
• 39 Essers BAB, Prins MH. Methods to measure treatment satisfaction in patients with pulmonary embolism or deep venous thrombosis. Curr Opin Pulm Med 2010; 16: 437-441.
• 40 Prins MH, Guillemin I, Gilet H. et al. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes 2009; 7: 30.
• 41 Prins MH, Marrel A, Carita P. et al. Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the ’Perception of Anticoagulant Treatment Questionnaire’ (PACT-Q). Health Qual Life Outcomes 2009; 7: 9.
• 42 Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27: S217-S232.
• 43 Scott PA, Pancioli AM, Davis LA. et al. Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients. Stroke 2002; 33: 2664-2669.